Skip to main content

Table 1 Summary of different assays for PD-L1 in the studies

From: Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy

Author (year) Sample size WHO grade Assay Material Tissue samples Antibody Staining patterns Cut-offa Rate (%)b
Wintterle et al. (2003) 10 III + IV IHC Frozen sections Full slides 5H1 NM Presence of PD-L1 staining 100
Wilmotte et al. (2005) 54 II–IV IHC Frozen sections Full slides MIH1 Membranous/cytoplasm Presence of PD-L1 staining 85.2
Yao et al. (2009) 48 I–IV IHC Frozen sections Full slides MIH1 (Ebioscience) Membranous/cytoplasm NM NM
I–IV WB Fresh tissues Full slides Anti-PD-L1 (R&D Systems) NM NM 75.0
Avril et al. (2010) 20 IV IHC PE NM Anti-PD-L1 (Clinisciences) NM >25% 45.0
Liu et al. (2013) 17 III + IV IFC Frozen sections NM Anti-human PD-L1 (558065; BD PharMingen) NM Presence of PD-L1 staining 76.5
Berghoff et al. (2014) 135 IV IHC PE Full slides 5H1 Membranous >5% 34.8
Diffuse/fibrillary Presence of PD-L1 staining 82.9
Nduom et al. (2015) 99 IV IHC PE Tissue microarray EPR1161(2) (Abcam) Membranous ≥1% 60.6
Zeng et al. (2016) 229 I–IV IHC PE Tissue microarrays Rabbit anti-PD-L1 Membranous/cytoplasm >5% 51.1
Garber et al. (2016) 345 I–IV IHC PE Full slides SP142 (Spring Biosciences) Membrane >5% 6.1
Pooled data 957         44.7
  1. Abbreviations: IHC immunohistochemistry, IFC immunofluorescence histochemistry, WB western blot, PE paraffin-embedded specimens, NM not mentioned
  2. aCut-off value to determine positivity
  3. bThe rates of patients with glioblastomas with any PD-L1 protein expression on tumor cells